1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cancer of Pituitary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tashjian, AH; Yang, JP | 1 |
| Bray, D; Garzon-Muvdi, T; Ioachimescu, A; Maldonado, J; Mayol, M; Medina, EJ; Morales, B; Neill, S; Porto, E; Pradilla, G; Read, W; Revuelta Barbero, JM; Rodas, A; Zohdy, YM | 1 |
1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cancer of Pituitary
| Article | Year |
|---|---|
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Topics: Humans; Indazoles; Male; Middle Aged; Pituitary Neoplasms; POU Domain Factors; Prolactinoma | 2023 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cancer of Pituitary
| Article | Year |
|---|---|
Platelet-activating factor affects cytosolic free calcium concentration and prolactin secretion in GH4C1 rat pituitary cells.
Topics: Animals; Calcium; Calcium Channels; Cell Line; Diterpenes; Dose-Response Relationship, Drug; Egtazic Acid; Ginkgolides; Kinetics; Lactones; Pituitary Neoplasms; Platelet Activating Factor; Potassium Chloride; Prolactin; Rats; Thyrotropin-Releasing Hormone; Verapamil | 1991 |